An unblinded randomized study of influenza A/H1N1 2009 (swine flu)resistance under standard and extended duration Oseltamivir treatment
An unblinded randomised study to evaluate viral resistance (viral shredding) following standard and extended duration Oseltamivir treatment in patients with influenza A/H1N1 2009
Roche Products NZ Ltd
125 participants
Aug 5, 2009
Interventional
Conditions
Summary
The study will show whether the influenza virus is more likely to develop resistance to Tamiflu during treatment while using a standard 5 day course compared with an extended 10 day course.
Eligibility
Inclusion Criteria7
- Male and non-pregnant female subjects age greater than or equal to 5 years:
- A positive Influenza A Rapid Antigen Test (RAT) performed on an adequate nasopharyngeal specimen, in accordance with the manufacturer’s instructions. If the RAT is negative but, in the investigator’s opinion, there is strong clinical suspicion of any type of influenza then the subject may be enrolled.
- Presence of fever at the time of screening of greater or equal to 37.8 degrees celius (greater or equal to 100.04 degrees F) taken orally. A subject self-report of a history of a fever or feverishness within the 24 hours prior to screening will also qualify for enrolment in the absence of documented fever at the time of screening.
- Presence of at least one respiratory symptom (cough, sore throat, or nasal symptoms).
- Onset of symptoms no more than 48 hours before presentation for screening.
- Female of non-childbearing potential, either surgically sterilised or at least one year post-menopausal. If a female is of childbearing potential, she must be abstinent or using adequate contraceptive precautions, including but not limited to the following: barrier methods (condom or diaphragm), intrauterine contraceptive device (IUCD), oral contraceptive, or equivalent hormonal contraceptive (e.g. progesterone-only implant, cutaneous hormonal patch, injectable contraceptives) and agree to continue such precautions for the duration of the study.
- Written informed consent.
Exclusion Criteria14
- Women who are pregnant or breast-feeding.
- Presence of clinically significant signs of acute respiratory distress
- History of severe chronic obstructive pulmonary disease (COPD).
- History of heart failure of angina requiring daily pharmacotherapy with symptoms consistent with New York Heart Association Class III or IV functional status within the past 12 months.
- History of chronic renal impairment requiring hemodialysis and/or known or suspected to have moderate or severe renal impairment (actual or estimated creatinine clearance <50mL/min).
- Clinical evidence of worsening of any chronic medical condition (temporarily associated with the onset of symptoms of influenza) which, in the investigator’s opinion, indicated that such finding(s) could represent complications of influenza.
- Current clinical evidence, including clinical signs and/or symptoms consistent with otitis, bronchitis, sinusitis and/or pneumonia, or active bacterial infection at any body site that requires therapy with oral or systemic antibiotics.
- Presence of immunocompromised status due to chronic illness, previous organ transplant, or use of immunosuppressive medical therapy which would include oral or systemic treatment with >10 mg prednisone or equivalent on a daily basis within 30 days of screening.
- Currently receiving treatment for viral hepatitis B or viral hepatitis C.
- Presence of known Human immunodeficiency virus (HIV).
- History of alcohol abuse or drug addiction within 1 year prior to admission in the study.
- Current participation in a study of any investigational drug.
- Any other medical condition which, in the opinion of the investigator, would preclude safe participation in the clinical trial.
- Known hypersensitivity to Oseltamivir.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Adults or subjects >40 kg will be randomised in a ratio of 1:1 to a standard 75mg twice a day for 5 days or an extended 75mg tiwice a day for 10 days. The mode of adminstration is an oral capsule Children will be randomised in a ratio of 1:1 to a standard dose for 5 days or an extended dose for 10 days powder for oral suspension, which when reconstituted with water to a concentration of 1.2% contains 12 mg/mL oseltamivir. The dose is calculated by weight. 15 kg or less 60 mg per day divided into 2 doses 15–23 kg 90 mg per day divided into 2 doses 24–40 kg 120 mg per day divided into 2 doses
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12610000361000